Bayer Pharma Aktiengesellschaft
1987: PhD in Organic Chemistry at Univ. Mainz with Prof. Kunz (Synthesis and
stereodifferentiating complexation of Enniatin-like cyclodepsipeptides)
1987-1988: Post Doc: Max Planck grant at MPI for Biochemistry in Munich (Prof.
1988-2002: Bayer AG Central Research; Leverkusen
2002-today: Bayer Pharma AG, Global Drug Discovery; Wuppertal
Research Fellow, Medicinal Chemistry;
Current Research Focus: Drug Delivery Systems and Prodrugs; Antibody-Drug
12 publications and ~50 patents and patent applications
Antibody Drug Conjugates: Challenges in the interface between proteins and small
Antibody Drug Conjugates represent a promising option for cancer treatment
combining the specificity of mAbs with high potentcy of cytotoxic agents. A
general introduction into the field with a particular focus on the technical
challenges and progress with different toxophor linker chemistries including a
case study will be provided.